The end of the year and the beginning of the year are typical of gyms. This is because registration

South Korea's market for GLP‑1 obesity treatments has surged, cited at KRW 2,013 billion in Q3, with WeGovi capturing roughly 70% of the market (reported 142 billion won) and cumulative WeGovi sales reported at 79.4 billion won (Q1), 133.8 billion won (Q2) and 350.3 billion won (Q3). Newly launched Mountaineer recorded 28.4 billion won in sales within two months of its August launch. Rapid consumer uptake is diverting demand from gyms and implies near‑term revenue upside for makers of GLP‑1 drugs, though clinicians warn of muscle loss and other side effects and stress exercise remains necessary for healthy weight loss.

Analysis

Market structure: GLP‑1 obesity drugs concentrate value at large biopharma (global winners: NVO, LLY) and service vendors (IQV) while displacing low‑value, high‑price fitness services (local gyms, boutique PT). Korea data shows ~KRW2.0tn Q3 market with ~70% share to a single product — a pattern that implies winner‑takes‑most economics, pricing power but also vulnerability to wholesale price edits (already cut in August).

Risk assessment: Near term (0–3 months) upside is media‑driven demand; short term (3–12 months) key tail risks are payer restrictions, safety headlines, or active‑ingredient supply shortages that could compress sales by >20–30% vs. current trajectory. Longer term (12–36 months) mechanical risks include muscle‑loss/clinical liability and policy responses (reimbursement caps) that could structurally reduce ASPs; monitor regulatory notices and formulary actions as binary catalysts.

Trade implications: Allocate asymmetric exposure to manufacturers and data services while trimming consumer fitness names: prioritize LLY/NVO and IQV (service tailwinds) over Planet Fitness (PLNT) and low‑margin boutique operators; implement 6–12 month call spreads to cap capital at risk while capturing adoption momentum. Use pair trades (long LLY, short PLNT) to isolate therapy demand vs. leisure spend.

Contrarian angles: Consensus underestimates gyms' adaptability — strength/rehab studios and physical therapy could regain share and command higher ARPU, producing a rotate‑within‑discretionary trade (short mass‑market chains, long premium studios). Also be wary of supply constraints keeping prices and margins high (if supply < demand for 6–12 months, upside persists), so a knee‑jerk sell on “GLP‑1 saturation” could be overdone.

Key Decisions for Investors

• Establish a 2–3% long position in Eli Lilly (LLY) and Novo Nordisk (NVO) combined (target 60% LLY / 40% NVO), horizon 6–12 months; thesis: continued rapid uptake could re‑rate sales by +20–30% absent regulatory shocks.
• Allocate 1–1.5% long IQV (IQV) to capture increased market research/real‑world evidence spend; time to hold 3–6 months ahead of quarterly results that should show increased services to GLP‑1 rollouts.
• Implement a pair trade: long 1.5% LLY, short 1% Planet Fitness (PLNT) — expected enrollment pressure at mass‑market gyms over next 6 months; trim short if PLNT margin expansion or new service pivot announced.
• Buy a 9–12 month LLY call spread (buy ATM, sell ~25–30% OTM) sized at 0.5–1% notional to capture upside while limiting premium paid; if newsflow shows payer restrictions (formulary exclusion or >20% price cut) within 30–90 days, close spread.
• Set hard stop / monitoring rule: if any major market (US/EU/Korea) announces reimbursement caps or wholesale price cuts >20% impacting top manufacturers within 60 days, reduce NVO/LLY exposure by 50% and shift proceeds into specialty fitness/physical therapy operators.